Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AML drug venetoclax under Real-World watch in south korea

NCT ID NCT04826523

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how safe and effective the oral drug venetoclax (Venclexta) is for adults with acute myeloid leukemia (AML) when used in everyday medical practice. About 150 people in South Korea took the drug as prescribed by their doctor for up to 7 months. Researchers tracked side effects and how well the cancer responded to treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Venetoclax (Venclexta) tablets
What this could lead to
If successful, this study will confirm that venetoclax is a safe and effective treatment option for AML in everyday medical practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Side effects like serious infections or low blood counts are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

150 people

The number who actually took part.

Started

Apr 2021

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Acute Myeloid Leukemia (AML) participants who are prescribed Venetoclax within the approved label shall be enrolled in the study according to the clinical judgment of the physician in charge of the study.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: --Acute Myeloid Leukemia (AML) participants who have been prescribed oral Venetoclax tablets for the first time according to the approved label. Exclusion Criteria: * Participants with contraindications to Venetoclax as listed on the approved local label. * Participants receiving Venetoclax in clinical trials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myeloid leukemia (AML) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myeloid leukemia (AML)

Contacts and locations

Locations

  • Chonnam National University Hwasun Hospital /ID# 257478

    Hwasun-gun, Jeonranamdo, 58128, South Korea

  • Gachon University Gil Medical Center /ID# 239008

    Incheon, Gyeonggido, 21565, South Korea

  • Korea University Anam Hospital /ID# 231022

    Seoul, Seoul Teugbyeolsi, 02841, South Korea

  • Kosin University Gospel Hospital /ID# 257399

    Busan, Busan Gwang Yeogsi, 49267, South Korea

  • Kyungpook National University Hospital /ID# 257398

    Daegu, Daegu Gwang Yeogsi, 41944, South Korea

  • Pusan National University Hospital /ID# 239010

    Busan, Busan Gwang Yeogsi, 49241, South Korea

  • Samsung Medical Center /ID# 239009

    Seoul, Seoul Teugbyeolsi, 06351, South Korea

  • Seoul National University Hospital /ID# 257477

    Seoul, Seoul Teugbyeolsi, 03080, South Korea

  • Yeungnam University Medical Center /ID# 239007

    Daegu, 42415, South Korea

  • Yonsei University Health System Severance Hospital /ID# 239006

    Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.